Lv0
0 积分 2025-04-28 加入
10.1016/0163-7258(94)90023-x
7小时前
已完结
Daily briefing: CAR-T proves its worth in hard-to-treat solid tumours
22天前
已完结
IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies
1个月前
已完结
Correlation of low B7-H6 expression with efficacy of immunotherapy inpatients with melanoma
2个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
2个月前
已完结
皖公网安备34019202002308
